The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial
Abstract
Purpose: To investigate the efficacy and safety of zoledronic acid for the treatment of bone metastases from breast cancer. Patients and Methods: Women with bone metastases (N = 228) were randomly assigned to receive 4 mg zoledronic acid (n = 114) or placebo (n = 114) via 15-minute infusions every 4 weeks for 1 year. The primary efficacy end point was the skeletal-related event (SRE) rate ratio between treatment groups. An SRE was defined as pathologic fracture, spinal cord compression, and radiation or surgery to bone. Secondary end points included percentage of patients with at least one SRE, time-to-first SRE, and Andersen-Gill multiple-event analysis. Results: The SRE rate ratio at 1 year (excluding HCM and adjusted for prior fracture) was 0.61 (permutation test; P = .027), indicating that zoledronic acid reduced the rate of SRE by 39% compared with placebo. The percentage of patients with at least one SRE (excluding HCM) was significantly reduced by 20% by zoledronic acid (29.8% v 49.6% for placebo; P = .003). Zoledronic acid significantly delayed time-to-first SRE (median not reached v 364 days; Cox regression; P = .007) and reduced the risk of SREs by 41% in multiple event analysis (risk ratio = 0.59; P = .019) compared with placebo. Zoledronic acid was well tolerated with a safety profile similar to placebo. No patient treated with zoledronic acid had grade 3 or 4 serum creatinine increase. Conclusion: Zoledronic acid significantly reduced skeletal complications compared with placebo across multiple end points in Japanese women with bone metastases from breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Cited by
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Saad, F., Lipton, A., Cook, R., Chen, Y., Smith, M., & Coleman, R. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 667
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Metadata
- Authors
- Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-20
- Volume
- 23
- Issue
- 15
- Pages
- 3314-3321
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142234592
- Cited by
- 546
- References
- 1
- FWCI
- 15.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1200/jco.2005.05.116
- The paper
- Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005). Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.05.116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.